Rachel Yu

Ms. Rachel Yu brings nearly two decades of experience in private equity, public market, and pharmaceutical R&D. in both China and the U.S.

Prior to joining Oceanpine Capital, Rachel spent over seven years at China Renaissance, serving as Partner of CR Life Star Fund and Managing Director of Healthcare and Life Sciences. During this tenure, she led approximately 30 high-profile private financings and equity investments totaling over $3 billion, with multiple portfolio company IPOs. Earlier in her career, Rachel served as Vice President, Head of Research in Beijing and Head of China's Healthcare Practice at Gerson Lehman Group (GLG), building substantial industry networks.

Prior to that, Rachel worked in the U.S. for a decade with distinguished roles including Equity Research Analyst covering U.S. Healthcare at Deutsche Bank and other top-tier investment banks, five-year tenure as researcher in Genentech R&D division.

Rachel holds an MBA degree from the University of Chicago Booth School of Business, a Master of Science degree in Molecular Pharmacology from the University of Missouri, and a Bachelor’s degree in Pharmaceutical Science from Guangdong Pharmaceutical University.